Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A two-period, open-label, randomized, parallel-group, partial cross-over study to evaluate the relative bioavailability and pharmacokinetics of two lumefantrine formulations in comparison to a reference formulation in healthy volunteers

Trial Profile

A two-period, open-label, randomized, parallel-group, partial cross-over study to evaluate the relative bioavailability and pharmacokinetics of two lumefantrine formulations in comparison to a reference formulation in healthy volunteers

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Jun 2018

At a glance

  • Drugs Lumefantrine (Primary)
  • Indications Malaria
  • Focus Pharmacokinetics
  • Sponsors Novartis Pharmaceuticals Corporation
  • Most Recent Events

    • 15 Jun 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top